ESTRO 2024 - Abstract Book

S1779

Clinical - Lung

ESTRO 2024

4. Radiosensitivity of Thymoma: Thymoma's intrinsic radiosensitivity further supports the use of SBRT in this patient population. The promising results achieved in our study reinforce the role of SBRT in managing thymoma recurrence effectively.

Conclusion:

In conclusion, our data confirm SBRT as a valid and promising approach for the treatment of recurrent thymoma. Its remarkable safety record, coupled with excellent local disease control and the ability to address multiple lesions simultaneously, makes it a compelling option for patients facing this challenging condition. As we continue to gather data and refine our techniques, SBRT may increasingly play a pivotal role in the multidisciplinary management of recurrent thymoma, ultimately improving patient outcomes and enhancing our understanding of this complex disease.

Keywords: Thymoma, SBRT, oligometastasis

2749

Digital Poster

Feasibility of SBRT with CK in the scenario of lung metastases re-RT: monoinstitutional experience.

Esmeralda Scipilliti, Rossella Di Franco, Valentina Borzillo, Giuseppe Totaro, Vincenzo Ravo, Sara Falivene, Paolo Muto

Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Department of Radiation Oncology, Naples, Italy

Purpose/Objective:

To evaluate feasibility and safety of SBRT with Cyberknife (CK) system in the scenario of geometrical overlap in re irradiation (re-RT), as proposed by the recent ESTRO-EORTC consensus.

Material/Methods:

We reviewed retrospectively data of 86 consecutive patients (pts) who received multiple Stereotactic Body radiotherapy (SBRT) with CK system for lung metastases at IRCCS Pascale between 2014 and 2023 and then divided those pts according to the recent ESTRO-EORTC consensus on re-RT. We evaluated all treatment plans in order to extrapolate volume overlaps and categorize them as re-RT type 1 (volume overlaps). The remaining targets were divided within the other main categories, re-RT type 2 or organ re-irradiation (depending on whether targets were located in the ipsilateral lung with concern for toxicity from cumulative doses or not). We focused on clinical available data on pts belonging to re-RT type 1 group